About the D2 Team

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid. Please click the logos below for more information on the role of each partner.

The University of Liverpool is both Sponsor for the DolPHIN 2 clinical trial and lead partner for the whole DolPHIN 2 project, responsible for overall programme management and implementation of the clinical trial, qualitative studies and pharmacoeconomic study.

×

The University of Cape Town (UCT) is responsible for recruitment, coordination and implementation of the clinical trial within South Africa.

The School of Public Health and Family Medicine at UCT is a strong multidisciplinary department in the Faculty of Health Sciences at the University of Cape Town. Their teaching, research and service extend to a wide range of settings and content areas consistent with the evolving disciplines of public health and family medicine.

×

The Tropical Clinical Trials Unit (tCTU) based within Liverpool School of Tropical Medicine (LSTM), is both responsible for the management of the DolPHIN 2 clinical trial and lead partner for the qualitative studies within the programme

Founded in 1898, LSTM was the first institution in the world dedicated to research and teaching in the field of tropical medicine. As a registered charity, they work across the world to fulfil their mission of reducing the burden of sickness and mortality in disease endemic countries, through the delivery of effective interventions which improve health and are relevant to the poorest communities.

As well as attracting more than 600 students from around the world as a teaching institution, LSTM provides technical assistance as a major component of their mission, with consultancies to improve health systems in developing countries whilst helping to inform their teaching and research agendas.

×

The Infectious Diseases Institute (IDI), Uganda, is one of the recruiting sites for the DolPHIN 2 trial. It is responsible for local coordination and implementation of the trial in Uganda as well as pharmacoeconomic research into the implementation of dolutegravir.

IDI is a Ugandan not-for-profit organisation whose Mission is to strengthen health systems in Africa, with a strong emphasis on infectious diseases, through research and capacity development. Established within Makerere University, the Institute began life in 2002 and currently provides care and treatment services to over 100,000 people living with HIV in urban and rural settings in Uganda which amounts to about 10% of the national effort. IDI also provides extensive prevention services and is a national referral centre for complicated cases of HIV.

×

The funder of the DolPHIN 2 project, Unitaid is an international organisation that invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. Unitaid is a hosted partnership of the World Health Organization (WHO).

×

Radboudumc is responsible for external monitoring of the clinical trial, ensuring that that it is carried out to a high quality standard, and in accordance with Good Clinical Practice (GCP) standards. Radboudumc is a University Medical Centre in the Netherlands which combines patient care, research, and scientific training. Their aim is to actively contribute to the development of reliable, innovative and affordable healthcare both in the Netherlands and abroad.

×

To sign up to our newsletter, please enter your details below: